Triplets Frontline Therapy Increases PFS for Patients with Previously Untreated Advanced Renal-Cell Carcinoma

In this MEDtalk, medical oncologist Laurence Albiges presents a phase 3 trial investigating potential benefits of using triplets in frontline therapy for patients with previously untreated advanced renal-cell carcinoma. Results suggest an
significantly longer PFS in patients treated with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) and Yervoy (ipilimumab) compared with nivolumab and ipilimumab alone.